Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05351554 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
A Phase 2 study, sponsored by Kinevant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05351554: Clinical Trial Phase 2 study, sponsored by Kinevant Sciences.
NCT05351554 is a Phase 2 study that was terminated before completion, run by Kinevant Sciences. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05351554, a Phase 2 study, was terminated before completion, sponsored by Kinevant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.
Primary Outcome
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this def
Interventions
- DRUG Namilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2022-12-13 |
| Phase | Phase 2 |
Why NCT05351554 stopped before completion
NCT05351554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Namilumab is the first listed.
NCT05351554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05351554 about?
NCT05351554 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis". A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.
What is the current status of trial NCT05351554?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-08-23. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT05351554?
The interventions under investigation include: Namilumab (DRUG).
Who is sponsoring clinical trial NCT05351554?
This trial is sponsored by Kinevant Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05351554's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI